Emerging strategies including novelcheckpoint targets (e.g., LAG-3, TIGIT), next-generation cellular therapies, cancer vaccines, and oncolytic viruses areunder active investigation to expand therapeutic options and improve patient outcomes. This evidence concerns the gene LAG3 and cancer.